IMMUTEP Ltd (IMMP)
Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987, and is headquartered in Sydney, Australia.
Address
LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
SYDNEY,, C3 NSW 2000
Founded
1987
Number of Employees
-
Website
http://www.immutep.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at IMMP make a trade.
Creating a free account takes less than one minute